All (95% CI) | No AHFS (95% CI) | AHFS (95% CI) | |
---|---|---|---|
n=628 | n=584 | n=44 | |
Age (years) | 67 (66 to 68) | 67.1 (66.1 to 68.2) | 65.3 (62.1 to 68.5) |
Male gender (%) | 73.7 (70.1 to 77.1) | 73.1 (69.3 to 76.6) | 81.8 (66.8 to 91.3) |
Ischaemic aetiology (%) | 64.8 (60.9 to 68.5) | 64.4 (60.5 to 68.4) | 68.2 (52.3 to 80.9) |
Diabetes (%) | 24.5 (21.2 to 28.1) | 22.9 (19.6 to 26.6) | 45.5 (30.7 to 61.0) |
HF hospitalisation in past year (%) | 22.8 (19.6 to 26.3) | 21.2 (18.0 to 24.8) | 43.2 (28.7 to 58.9) |
NYHA class | 2.19 (2.13 to 2.25) | 2.16 (2.1 to 2.23) | 2.55 (2.31 to 2.78) |
Systolic BP (mm Hg) | 121.9 (120.1 to 123.6) | 122 (120.1 to 123.8) | 120.2 (112.9 to 127.5) |
Diastolic BP (mm Hg) | 71.7 (70.7 to 72.7) | 71.8 (70.7 to 72.8) | 71.6 (67 to 76.1) |
BMI (Kg/m2) | 28.2 (27.6 to 28.7) | 28 (27.5 to 28.6) | 30.2 (27.8 to 32.5) |
Heart rate (bpm) | 73.2 (71.7 to 74.7) | 72.8 (71.3 to 74.3) | 78.5 (71.9 to 85.1) |
Hb (g/dL) | 13.8 (13.6 to 13.9) | 13.8 (13.6 to 13.9) | 13.5 (12.8 to 14.1) |
Sodium (mmol/L) | 139.3 (139 to 139.5) | 139.4 (139.1 to 139.6) | 138 (136.7 to 139.3) |
eGFR (mL/Kg/min) | 53.3 (52 to 54.6) | 53.4 (52.1 to 54.8) | 51.9 (46.6 to 57.3) |
LV end diastolic diameter (mm) | 58.7 (57.9 to 59.4) | 58.5 (57.7 to 59.3) | 60.7 (57.9 to 63.5) |
LV end systolic diameter (mm) | 49.1 (48.3 to 49.9) | 48.9 (48.0 to 49.8) | 51.4 (48.2 to 54.6) |
LV EF (%) | 31.3 (30.6 to 32) | 31.3 (30.5 to 32) | 31.6 (28.7 to 34.6) |
Radiological pulmonary congestion (%) | 24.9 (21.5 to 28.6) | 22.8 (19.5 to 26.6) | 52.4 (36.6 to 67.7) |
Furosemide dose at baseline (mg) | 55.7 (51.5 to 59.8) | 53.3 (49.1 to 57.6) | 86.4 (70.9 to 101.9) |
Ramipril dose at baseline (mg) | 5.0 (4.7 to 5.3) | 5.1 (4.8 to 5.4) | 3.5 (2.7 to 4.3) |
Bisoprolol dose at baseline (mg) | 3.2 (3.0 to 3.5) | 3.3 (3.1 to 3.5) | 2.9 (2.0 to 3.8) |
AHFS, acute heart failure syndrome; BMI, Body Mass Index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; NYHA, New York Heart Association.